ReviewFrontiers in endocrinology2019
Gut Dysfunction and Non-alcoholic Fatty Liver Disease.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review.Frontiers in nutrition · 2022Pooled it
- Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis.PloS one · 2021Pooled it
- The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial.Frontiers in endocrinology · 2022Trial
- Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients.Molecular systems biology · 2021Trial
- Underlying MASLD-induced gut microbiome dysbiosis and intestinal inflammation are key to poor outcomes in vibriosis infections in a preclinical model.Gut microbes · 2026Article
- From Policy to Practice: Knowledge gaps and training outcomes related to MASLD guidelines among medical officers in Chhattisgarh, India.BMC health services research · 2026Article
- Sucrose-free low-fat diet induces metabolic dysfunction through gut dysbiosis and colonic inflammation in mice.Frontiers in immunology · 2026Article
- Pathophysiology of depression and anxiety in metabolic dysfunction-associated steatotic liver disease.World journal of gastrointestinal pathophysiology · 2025Review
- Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics.The Journal of clinical investigation · 2025Review
- Study on the molecular mechanisms of rifaximin in the treatment of non‑alcoholic steatohepatitis based on theMolecular medicine reports · 2025Article
- Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease.Microbiome · 2025Article
- A new insight: crosstalk between neutrophil extracellular traps and the gut-liver axis for nonalcoholic fatty liver disease.Frontiers in immunology · 2025Review
- Gas Chromatography-Mass Spectrometry-Based Analyses of Fecal Short-Chain Fatty Acids (SCFAs): A Summary Review and Own Experience.Biomedicines · 2024Review
- Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.World journal of gastroenterology · 2024Review
- Insights into the Mechanisms of Action ofNutrients · 2024Review
- NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden.Life (Basel, Switzerland) · 2023Article
- The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives.International journal of molecular sciences · 2023Review
- Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression.Narra J · 2023Article
- Transcriptional and Epigenetic Alterations in the Progression of Non-Alcoholic Fatty Liver Disease and Biomarkers Helping to Diagnose Non-Alcoholic Steatohepatitis.Biomedicines · 2023Article
- Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the leading liver diseases worldwide. NAFLD is characterized by hepatic steatosis and may progress to an inflammatory condition termed non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma. It became evident in the last years that NAFLD pathophysiology is complex and involves diverse immunological and metabolic pathways. An association between intestinal signals (e.g., derived from the gut microbiota) and the development of obesity and its metabolic consequences such as NAFLD are increasingly recognized. Pre-clinical studies have shown that germ-free mice are protected against obesity and hepatic steatosis. Several human studies from the past years have demonstrated that NAFLD contains a disease-specific gut microbiome signature. Controlled studies propose that certain bacteria with rather pro-inflammatory features such as Proteobacteria or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.